


**Predictable Outcomes in Complex Bifurcations treated with TRYTON**




Courtesy of E. Grube MD and R. Müller MD

Courtesy of M. Kutcher MD

**2.5 mm Side Branch (19mm)**

**3.0 - 3.5 mm Side Branch (15 mm)**



**Only FDA approved device for bifurcation lesions**

**Ordering Information**

Product Codes	Diameter SB - MB (mm)	Length (mm)	Minimum Guiding Catheter Diameter	Maximum Post-expansion Diameter SB - MB (mm)	Nominal Pressure (atm)	RBP (atm)
<b>2.5 mm Side Branch</b>						
T52525191US	2.5 - 2.5	19	5F	3.0 - 4.0	8	14
T52530191US	2.5 - 3.0	19	5F	3.0 - 4.0	10	14
T52535191US	2.5 - 3.5	19	5F	3.0 - 4.0	10	14
<b>3.0 - 3.5 mm Side Branch</b>						
T53035151US	3.0 - 3.5	15	6F	4.0 - 4.5	8	14
T53540151US	3.5 - 4.0	15	6F	4.0 - 4.5	10	14

<sup>1</sup> Outcomes Tryton in Bifurcations Large Side Branches – RCT Subanalysis - Généreux Et Al - CCI 2016.

<sup>2</sup> Outcomes Tryton Conformatory Study Généreux, Et Al. JACCInterv. 2016.

<sup>3</sup> RCT Post-Hoc intended Cohort analysis (SB RVD  $\geq 2.25$ mm QCA); note that the RCT was not powered to show statistically significant differences in secondary endpoints or in primary endpoints in sub-populations.

<sup>4</sup> Device Success: Achievement of final in-stent residual stenosis <30% (by QCA) in SB using the assigned study device without malfunction.

<sup>5</sup> Procedural Success: Achievement of a final in-stent diameter stenosis of <50% (by QCA) using the assigned device and with any adjunctive devices, without the occurrence of cardiac death, Q wave or non-Q wave MI, or repeat revascularization of the target lesion during the hospital stay

<sup>6</sup> RCT Dedicated Bifurcation Stent Vs. Provisional – Généreux, Et Al. JACC. 2015

<sup>7</sup> Data on File With Tryton Medical Inc.

<sup>8</sup> Acute: within 24 hours; Subacute:  $\geq 1$  day - 30 days; Late: 31 days - 1 year; Very Late > 1 year

<sup>9</sup> Garg, et al. Euro Intervent. 2011; 6: 928-93

<sup>10</sup> Hildick-Smith, et al. Circulation 2010; 121: 1235-1243

<sup>11</sup> Chen, et al. J Am Coll Card. 2011; 57: 914-920


<sup>12</sup> Columbo, et al. Circulation 2009; 119: 71-78

<sup>13</sup> Urban, et al. NEJM. 2015; 373:21

For customer service, call 1.800.327.7714. For more information, visit [cordis.com/tryton](http://cordis.com/tryton)

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. For healthcare professionals only. Prior to use, refer to the instruction for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. WARNINGS: Use of the Tryton Side Branch Stent in appropriately sized main vessels and side branches is required for safe and effective performance of the device. Do not use the Tryton Stent in small side branches [ $<2.50$  mm in diameter by visual assessment or  $<2.25$  mm in diameter by quantitative coronary angiography (QCA)], as its use may lead to an increased risk of adverse cardiac events such as myocardial infarction and the need for repeat revascularization. To confirm appropriately-sized side branch diameters, the diameter of the pre-dilation balloon inflated to nominal pressure may be used as a reference. Alternatively, the use of quantitative imaging methods such as on-line quantitative coronary angiography, intravascular ultrasound or optical coherence tomography should be considered. Use of the Tryton Side Branch Stent, as with percutaneous coronary stent implantation procedures in general, is known to be associated with the following risks: Vessel thrombosis. Increased length of hospital stay relative to those of coronary balloon angioplasty alone. Judicious selection of patients to receive this device rather than balloon angioplasty alone is strongly advised. Infection secondary to contamination of the stent may lead to thrombosis, pseudoaneurysm or rupture. The stent may cause spasm, distal embolization, thrombus, or could migrate from the site of implantation. Excessive dilatation of the artery may cause vessel rupture and life-threatening bleeding. Stents may not be fully expanded during deployment, particularly in resistant lesions. Stent dislodgment from the balloon surface during deployment and/or dislodgment from the target site post-deployment can occur. Major bleeding.

© 2017 Cardinal Health. All Rights Reserved. Cordis and the Cordis LOGO are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. TRYTON is manufactured by Tryton Medical and distributed by Cordis. 155-9076 07/17



[cordis.com/tryton](http://cordis.com/tryton)


**TRYTON** Side Branch Stent

**Built for Bifurcation**


- Simplify treatment
- Superior procedural and device success<sup>1</sup>
- Predictable outcomes

## Treatment of Bifurcations is Challenging

### Varying Angulations




### Diameter Differences




## Simplify Treatment with TRYTON Side Branch Stent Technology Built for Bifurcations

The TRYTON Side Branch Stent is specifically designed to actively treat, protect and secure the entire bifurcation lesion, offering ease of implantation and complete main vessel stent integration.



Prior to use, please refer to the Instructions for Use available for download at [cordis.com/tryton](http://cordis.com/tryton)


## TRYTON Superior Device and Procedural Success<sup>3,4,5</sup> RCT Intended Population



### Superior Device Success<sup>4</sup>

TRYTON demonstrates **2.6x more device success** versus provisional treatment.

Device Success: < 30 % Residual Stenosis, without Malfunction



### Superior Procedural Success<sup>5</sup>

TRYTON demonstrates **1.3x more procedural success** versus provisional treatment.

Procedural Success: < 50 % Residual Stenosis, without TVF

## Predictable Outcomes Demonstrated In Largest Randomized Bifurcation Trial<sup>6</sup>

- ✓ Significant reduction in Percent Diameter Stenosis<sup>1,3</sup>
- ✓ DES-like TVR in complex lesions<sup>1,3</sup>
- ✓ 0% Late/Very Late Stent Thrombosis Rate<sup>3,7,8</sup>

